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Summary Erythema nodosum leprosum (ENL, Type 2 reactions) complicates
lepromatous and borderline lepromatous leprosy and can affect many organ systems,
often with irreversible damage. The reactions commonly occur in the 2 years after
starting treatment and often run a recurrent or chronic course, sometimes for many
years. Even with WHO multi-drug therapy about 30% of LL patients experience
ENL.
We review drug management of ENL focussing on data from controlled trials and
other studies. The treatment of ENL is difficult because high doses of steroids may be
required for prolonged periods and do not always control the inflammation.
The paradox of ENL is that it can be a life-threatening disorder and requires control
with immunosuppression which may itself pose life-threatening risks for patients.
Treatment with thalidomide provides an effective alternative to steroid therapy, gives
better long-term control and avoids the adverse effects of prolonged steroid therapy.
Controlled clinical trials have demonstrated that thalidomide rapidly controls ENL
and is superior to aspirin and pentoxifylline. However, thalidomide is teratogenic
when taken in early pregnancy and is unavailable in many leprosy endemic countries.
We discuss the role of thalidomide in treating ENL, the complications encountered
and risk reduction strategies that can be used. These include good patient selection
and counselling, close supervision and adequate access to appropriate contraception.
Further research is needed to improve the understanding and treatment of this
severe and debilitating complication of leprosy. Topics for research include:
i. The development of validated tools to measure the severity and/or activity of
ENL.
ii. A detailed assessment of the neurotoxic effects of thalidomide when used to
treat ENL.
iii. A well designed trial comparing thalidomide with prednisolone.
iv. The development of a safe and effective alternative to both steroids and
thalidomide.
Correspondence to: Steve Walker, Department of Infectious and Tropical Diseases, London School of Hygiene
and Tropical Medicine, Keppel St, London WC1E 7HT, UK (e-mail: drstevewalker@hotmail.com)
Lepr Rev (2007) 78, 197–215
0305-7518//064053+19 $1.00 q Lepra 197
Search Strategy
Papers for this review were identified by repeated searches of PubMed with various
combinations of the following search terms: ‘leprosy’, ‘erythema nodosum leprosum’, ‘type 2
reactions’, ‘steroids’, ‘corticosteroids’, ‘lepra’, ‘Hansen*’.
Searches of LILACS using the terms ‘eritema nodoso hansenico’ and ‘erythema nodosum
leprosum’ were also conducted.
References from the articles retrieved from the searches were also used.
All searches were complete to the end of July 2007.
Erythema Nodosum Leprosum and Complications
ENL is an immune mediated reactional state which commonly complicates lepromatous
leprosy (LL) and less frequently borderline lepromatous (BL) leprosy. It is characterised by
the presence of cutaneous nodules but other organ involvement and systemic upset may
occur.1 The condition is termed ENL regardless of the site of involvement. Jopling proposed
the term type 2 reaction to distinguish it from type 1 (reversal) reactions.2 The skin lesions
usually occur in crops as painful and tender erythematous papules or nodules. They develop
over a few hours, last for several days and then slowly subside often leaving some dark
staining of the skin.1 Lesions may also be pustular or bullous.3,4 Deeper lesions in more
severe episodes cause a panniculitis. In BL leprosy, ENL papules may develop in the sites of
existing BL lesions. Fever and malaise frequently accompany the skin lesions; in severe
episodes there may be hypotension and tachycardia which may mimic septic shock and
severe ENL can be life-threatening. ENL may also produce iridocyclitis, neuritis, arthritis,
dactylitis, lympadenitis, orchitis and nephritis.1 Nerves are often tender and enlarged but
usually the neuritis is less dramatic than that associated with type 1 reactions. However, loss
of nerve function may occur rapidly.1
The Operational Guidelines of the Global Strategy for Further Reducing the Leprosy
Burden published by WHO in 2006 describes ENL as a syndrome of ‘complex medical
problems requiring careful management by experienced clinicians’.5
There are no prospective clinical studies on the clinical features of ENL and no good data
on the frequency of particular features, duration or severity of ENL. In a retrospective study
in India Pocaterra et al. found that the mean time to presentation with ENL was 3.7 months
after starting multi-drug therapy (MDT).6 However, patients may present with ENL as their
first manifestation of leprosy. ENL may continue for many years and we have had patients at
The Hospital for Tropical Diseases in London who have continued to have ENL for 7 years or
more. ENL may also occur after completion of MDT.
Three patterns of ENL were identified in a cohort of 82 Indian patients with ENL; single
acute episodes, recurrent acute episodes and chronic ENL.6 Acute single episodes were
defined as a single episode responding to steroid treatment and accounted for only 6% of
episodes, acute multiple ENL comprised recurrent episodes with periods off all treatment,
and chronic when patients needed steroid treatment for more than 6 months. The acute
multiple and chronic types accounted for 32% and 62% of the case types respectively. Murata
recognised that the condition ‘may be acute, subacute, or chronic’ in the 1912 description in
which the term ENL was first suggested.7
ENL is debilitating and adversely affects the morale of even the most optimistic.
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Recurrent skin lesions may result in scarring and inflammation of subcutaneous tissue
may cause fixation and reduce mobility in joints.1 In the eyes chronic iridocyclitis leads to
synechiae formation, glaucoma and blindness.8 The neuritis associated with ENL may result
in permanent nerve function impairment. The orchitis results in testicular atrophy which if
bilateral may result in hypogonadism and sterility. Men with leprosy are at increased risk
of osteoporosis and this is associated with hypogonadism.9 The possible association of
osteoporosis with ENL and corticosteroid therapy has not been investigated. Secondary
amyloidosis may occur if the reaction is inadequately controlled.
There is no validated scale for assessing severity of ENL. However, various authors have
defined mild disease as the presence of less than 10 skin lesions with no systemic symptoms.
Moderate disease can be defined as that present when multiple skin lesions are present and
severe when lesions are pustular or ulcerating and/or there is other organ system
involvement.10
In the Indian study the typical patient with ENL was a male aged 34.7 years who
experienced chronic ENL over a 2-year period.6 These patients are likely to be family wage
earners so ENL also has serious economic and social consequences which have not been
documented.
Epidemiology and Risk factors
The published data suggests that LL and BL patients still have high rates of ENL even those
taking WHO MDT. The most appropriate data sets are those that report on the BL and LL
subgroups of the MB category since it is these patients who are at risk of developing ENL.
There is wide geographical variation in the prevalence of ENL with high rates in Asia and
Brazil and probably lower rates in Africa although there is little data from Africa.
A retrospective study of clinic-based Indian patients 1990–2000 found a rate of almost 50%
in those with LL and 9% in BL cases6 and another retrospective hospital study from Nepal of
649 cases of BL leprosy and LL between 1989 and 1997 reported an ENL rate of 33% in LL
cases and 11% in BL cases.11 A study from Brazil of reactional episodes during a 24-month
period of MB MDT found that 31% of individuals experienced ENL.12 Two prospective
studies from Thailand found overall rates of 37% and 12%.13,14 ENL rates are much lower
when coming from field studies of MB patients as in the Ethiopian AMFES Study which
reported 5·3%.15 Rates are also likely to be lower when patients are diagnosed earlier and
when they are only followed for a year during MDT. Both the Nepali and Indian studies found
that LL disease and a bacterial index (BI) greater than 4 at diagnosis were risk factors for
ENL. In the latter study LL patients were 8·4 times more likely to develop ENL than those
with BL disease. Individuals with BL leprosy with a BI of 4 or more were 5·2 times more
likely to have ENL than BL patients with a BI of less than 4.
Pathophysiology
The principal pathology underlying ENL is antigen-antibody complex formation and
deposition in tissues. This results in local activation of complement and development of local
inflammation with neutrophil polymorph migration to the lesions. Direct immunofluores-
cence studies have demonstrated granular deposits of immunoglobulin and complement in
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the dermis in most ENL lesions but not in those of uncomplicated LL disease.16 Other
workers have also demonstrated the presence of immune complexes in cutaneous ENL
lesions.17,18
Tissue oedema and fibrinoid necrosis in vessels may also be present. ENL lesions
classically show an intense perivascular infiltrate of neutrophils throughout the dermis and
subcutis.19
There is T lymphocyte and macrophage activation and expression of mRNA for tumour
necrosis factor (TNF) and interleukin (IL)-12 in the skin.20 High levels of circulating TNF
have been found in the serum of some individuals with ENL.21,22 In the Brazilian study not all
patients had high levels of TNF and clinical improvement was not necessarily related to TNF
levels. TNF levels in individuals in Nepal with milder ENL reactions have been found to be
low.23 In vitro peripheral blood mononuclear cells from individuals with ENL secrete
increased amounts of TNF following stimulation by M. leprae or M. leprae antigens
compared to individuals with other forms of leprosy.24,25 There is no single diagnostic test
which confirms the diagnosis of ENL.
Management of ENL
Individuals should continue taking MB MDT and those presenting with ENL should be
commenced on MDT as well as specific treatment for ENL. Analgesics and antipyretic agents
can be used for milder disease.
ENL may also be triggered by intercurrent infections and psychological stress. A wide
differential diagnosis should be remembered in individuals in whom ENL is relapsing or not
responding to treatment.
CORTICOSTEROIDS
The use of adrenocorticotrophic hormone in the management of ENL was first reported by
Roche et al. in 195126 and corticosteroids remain the mainstay of treatment for ENL but they
are often required for prolonged periods at high doses.6 The treatment of more severe
reactions is often started at a dose of prednisolone 60 mg daily and pulsed steroid therapy in
recurrent disease has been reported in two small studies.27,28 The Indian study by Pocaterra
et al. shows how poor the control given by corticosteroids is in patients with chronic ENL
(Figure 1.) with individuals needing repeated high does of steroids and taking an average of
421 mg of prednisolone per month.
Individuals with chronic recurrent ENL extending over many years are at risk of
developing complications secondary to prolonged corticosteroid therapy and may require
alternative treatments. Sugumaran described the adverse effects of steroid therapy in 249
patients with ENL. This study was uncontrolled but reported higher rates of cataract, diabetes
and tuberculosis in the ENL group compared to a group of patients receiving steroids for type
1 reactions.29 A fatal case of Strongyloides stercoralis hyperinfection following steroid
treatment of ENL has also been reported.30
There are no data from controlled studies regarding the treatment of neuritis or
iridocyclitis associated with ENL.
The ILEP Technical Bulletin on the management of ENL recommends treating severe
ENL with corticosteroids at a starting dose of 30–60 mg and reducing every week by
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5–10 mg. It notes that a maintenance dose of 5–10 mg may be needed for several weeks to
prevent recurrence of ENL.10
The 1998 WHO Expert Committee on Leprosy report discussed the management of type 1
(reversal) reactions and ENL together31 advising that ‘severe ENL can be treated with
prednisolone, as for reversal reaction’ (a 12-week course of prednisolone). This overlooks the
chronic, recurrent nature of ENL and is not supported by any data. We agree with the recent
WHO Global Strategy statement that patients with ENL should be managed by staff with
experience of the condition. However, the document lacks specific guidance and states that
‘Short courses of steroids are often used, but other drugs are also useful.’5 For those
individuals with clinically significant ENL a short course of steroids will rarely give adequate
control of the ENL.
CLOFAZIMINE
Treatment with clofazimine improves ENL and is a mild anti-inflammatory.32 However,
clofazimine therapy does not control severe ENL and takes 4 to 6 weeks to become active.
The daily dose of 50 mg in MB MDT probably protects at-risk individuals from ENL.
This has never been formally tested but a multi-centre study of different chemotherapy
regimes in patients with lepromatous leprosy showed that regimes containing clofazimine
given 100 mg three times a week for 5 years were associated with a lower rate of ENL.33
The protective effect of clofazimine in preventing ENL is lost after 1 year when MB MDT is
stopped. This beneficial effect will be shortened further if uniform MDT is introduced.
The dose of clofazimine can be increased to 300 mg daily in those with ENL, but may
worsen clofazimine pigmentation and increase the risk of clofazimine crystal enteropathy.34,35
Figure 1. Clinical indices in a chronic case of ENL. Reproduced from Pocaterra L, Jain S, Reddy R et al. Clinical
course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg. 2006
May; 74(5):868-79. MB-MDT ¼ Multidrug therapy for multibacillary disease, S&S ¼ Symptoms and signs,
BI ¼ Bacterial index.
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The WHO Expert Committee recommended that the drug should not be maintained at this dose
(300 mg daily) for more than a year.31
THALIDOMIDE
Thalidomide was first developed in 1954 and subsequently marketed in Europe, Australia and
Canada as a sedative and anti-emetic. The drug was not approved in the USA by the Food and
Drug Administration because of concerns about safety and neurotoxicity.
Reports of limb and other congenital abnormalities in the children of women who had
taken thalidomide during pregnancy led to the drug being withdrawn from European markets
in 1961. About 10,000 children have abnormalities attributed to intrauterine exposure to
thalidomide.
Thalidomide is a racemic glutamic acid analogue composed of two enantiomers R- and S-
thalidomide (stereoisomers that are mirror images of one another) which interconvert under
physiological conditions. The two enantiomers have differing properties; one is a more potent
suppressor of TNF release by stimulated peripheral blood mononuclear cells whilst the other
is sedative.36 Thalidomide undergoes hydrolysis at pH 7 in aqueous solution and this
degradation leads to the formation of more than 20 products which are responsible for the
activity. The exact mechanisms of action of these products is not clear but TNF, interferon-g,
interleukins 10 and 12, cycloxygenase 2 and possibly the pro-inflammatory transcription
factor nuclear factor k B (NF-kB) are all affected.37 Thalidomide has effects on angiogenesis,
immune function and inflammation. In vitro work has demonstrated that M. leprae induced
activation of NF-kB in a Schwann cell line leading to transcription repression mediated by
TNF is inhibited by thalidomide.38
In 1965 Sheskin reported the effectiveness of thalidomide in the management of ENL.39
Thalidomide is used to treat dermatological conditions such as lupus erythematosus, nodular
prurigo, aphthous ulceration and Bec¸het’s syndrome when they are refractory to other
treatments.40 Thalidomide is effective in the management of myeloma.41
THALIDOMIDE AND ENL
The effectiveness of thalidomide in ENL is primarily due to its action on TNF but other
mechanisms may contribute to its anti-inflammatory effect.
Eight Brazilian patients, who had ENL with systemic symptoms and elevated serum TNF,
when treated with thalidomide had an associated reduction in the TNF levels. Recurrence of
the ENL after cessation of thalidomide was again associated with an elevation in serum TNF
levels.42
Treatment with thalidomide in the study of mild ENL from Nepal although resulting in
clinical improvement was associated with an unexpected rise in plasma TNF levels and
increased expression of IL-2 by CD4 and CD8 þ cells at day 7.23 In this group TNF levels
were lower than in control patients and the authors postulate that TNF levels are elevated in
individuals with more severe ENL with systemic manifestations. Thalidomide treatment was
associated with a reduction in plasma soluble 1L-2 receptor, a marker of inflammation but the
mechanism of this is unclear.
In two patients with successfully treated ENL thalidomide therapy was associated with a
reduction in the numbers of circulating CD4 þ lymphocytes.43
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Thalidomide-associated increases in TNF have been reported in other disease states such
as HIV related oral aphthous ulceration.44 Thalidomide was associated with a good clinical
response. However a randomised controlled trial of thalidomide in life-threatening toxic
epidermal necrolysis (a TNF mediated condition) was ended early because of an excess
mortality in the thalidomide arm of the study which was associated with higher plasma
concentrations of TNF.45
Table 1 shows prospective controlled trials of thalidomide in ENL. Only two studies have
been completed since the introduction of MDT.46,47
The double blind randomised study of 22 patients by Villahermosa et al.47 compared
thalidomide 100 mg daily with 300 mg daily given for 1 week. The lower dose group then
received 50 mg daily for 2 weeks followed by dummy capsules for 4 weeks. The group that
initially received 300 mg of thalidomide was weaned down to zero over the following 6
weeks. There was no significant difference in the response of the two groups at the end of the
first week of treatment with thalidomide. The lower dose group however experienced a
statistically significant flaring of skin lesions during the 7-week treatment period. Global
assessment scores of symptom severity improved on thalidomide. The three individuals
deemed to be treatment failures were all in the higher dosage arm of the study.
Sales et al. recruited 44 Brazilian patients with ENL into a double blind randomised
controlled trial comparing pentoxifylline and thalidomide.46 Individuals with neuritis were
excluded and follow-up was short at 30 days. Thalidomide was more effective than
pentoxifylline but one can not be confident that ENL severity was similar in the two groups.
The open trial by Iyer and Ramu48 used thalidomide 300 mg daily in 36 controls for 8
weeks and then maintained them on 50 mg daily for up to 1 year whilst studying the effect of
clofazimine 300 mg in ENL. The onset of action was more rapid with thalidomide but the
effect was not sustained as well as with clofazimine possibly because of the relatively low
dose of thalidomide used for maintenance.
Iyer et al. published a double blind trial comparing thalidomide 400 mg daily with aspirin
in 92 patients treated for 7 days.49 Thalidomide was faster and more efficacious in reducing
fever and the number of skin lesions. The effect on nerve and eye involvement was ‘less
pronounced’ but still deemed to be superior to that of aspirin.
A double blind study of 10 corticosteroid-dependent Malaysian patients demonstrated
that thalidomide 300 mg daily was superior to placebo in reducing steroid requirement.50
The same centre also examined the effect of thalidomide 300 mg in individuals with
moderately severe ENL i.e. those not requiring continual corticosteroids. The severity of
ENL was less during therapy with thalidomide than it was during administration of the
placebo.51
Sheskin and Convit’s double blind study in 59 Venezuelans, over a quarter of whom were
women, demonstrated that thalidomide 400 mg daily was associated with a statistically
significant improvement when compared to placebo.52 An earlier single blind study by
Sheskin53 used thalidomide 400 mg followed by placebo in a subsequent reaction.
The thalidomide was more effective than the placebo in all 13 patients studied.
The effect of thalidomide on non-cutaneous clinical and laboratory parameters is
commented on to varying degrees in these studies. An improvement in neuritis is reported in
three but without documenting how this was assessed.47,48,52
There have been numerous open uncontrolled studies reporting the effectiveness of
thalidomide in the management of ENL. The studies of both types whether controlled or not
often report the rapidity of onset of the effect of thalidomide in controlling symptoms.
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Table 1. Prospective studies using thalidomide in type 2 reactions
Author Year
Country Type of study Entry criteria
Total number
enrolled (number of
women) Intervention Outcome measures
None cutaneous
effects of
thalidomide
assessed in study Conclusion
Sales46 2007 Brazil Randomised,
controlled double
blind
ENL without
neuritis
44 (6) Thalidomide
300 mg/day or
pentoxifylline
1·2 g/day
Partial or total
improvement
Yes Thalidomide
superior to
pentoxifylline.
Villahermosa47
2005 Phillipines
Randomised,
controlled double
blind
Biopsy confirmed
ENL. ^ 10 lesions
22 (0) Thalidomide
100 mg/day or
300 mg/day for one
week then tapered
to zero.
%age change in
number of lesions
Yes No difference in
speed of onset of
improvement.
Improvement
sustained in higher
dosage group.
Iyer48 1976 India Randomised
controlled
Recurrent ‘reactive
episodes’
lepromatous
patients
72 (0) Clofazimine
300 mg or
thalidomide 300 mg
for 8 weeks
Time taken for
control of reactions
No Improvement
maintained more by
clofazimine treated
group.
Iyer49 1971 India,
Mali, Somalia,
Spain
Double blind ENL, neuritis or
nerve function
impairment
92 (not stated) Thalidomide
400 mg or aspirin
1600 mg daily
Improvement in
clinical signs
Yes Thalidomide
superior in
managing skin
lesions, fever, nerve
and eyes and testes,
lymph nodes liver
and spleen.
Waters50 1971
Malaysia
Double blind,
placebo controlled
Steroid dependent
biopsy proven ENL
10 (0) Thalidomide
300 mg daily or
placebo
Steroid requirement No Steroid requirement
reduced during
thalidomide
treatment period.
Pearson51 1969
Malaysia
Double blind,
placebo controlled
ENL 12 (1) Thalidomide
300 mg daily or
placebo
Clinical, laboratory
and additional
therapy required
Yes Severity of ENL
less during
thalidomide
treatment
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Table 1. continued
Author Year
Country Type of study Entry criteria
Total number
enrolled (number of
women) Intervention Outcome measures
None cutaneous
effects of
thalidomide
assessed in study Conclusion
Sheskin52 1969
Venezuela
Double blind,
placebo controlled
Lepromatous
leprosy with
manifestations of
‘lepra’ reaction
52 (15) Thalidomide
400 mg daily or
placebo
Improvement Yes Thalidomide
statistically
significant
difference
compared to
placebo
Sheskin53 1965
Israel
Placebo Lepra reactions of
lepromatous
leprosy patients
13 (3) Thalidomide
varying doses
Improvement
within 48 hours
No Therapies
containing
thalidomide
brought about
clinical
improvement,
whereas placebo
did not
T
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Thalidomide was approved by the FDA in the USA in 1998 ‘in the acute treatment of the
cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as
maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL
recurrences.’54 Thalidomide may be prescribed on a named patient basis in the UK although
the European Medicines Agency declined to licence it for ENL. The Australian Drug
Evaluation Committee approved the use of thalidomide in myeloma and ‘cutaneous
manifestations of moderate to severe erythema nodosum leprosum’. The drug is
manufactured and available in India and Brazil.55 Brazilian law forbids the sale of
thalidomide by commercial pharmacies and the amount dispensed is restricted. Physician and
patient must sign a declaration that adequate counseling has been provided.56
The WHO Expert Committee advises that thalidomide should only be given to men or
post-menopausal women who are dependent on corticosteroids.31 The ILEP Technical
Bulletin acknowledges the effectiveness of thalidomide and states that ‘It has fewer adverse
effects than corticosteroids’. However, it goes on to say that ‘women of child-bearing age
should never be given thalidomide’.10
Thalidomide is a good choice in men or post-menopausal women with difficult to manage
ENL. Women of childbearing age should also not be denied an effective and sometimes life-
saving drug provided that they and their physicians understand the risks associated with
taking thalidomide.
Physicians must undertake a detailed assessment of the risks as well as the benefits before
prescribing thalidomide. The patient and their partner should be educated about the drug and
the adverse effects associated with it.
Drowsiness is a problem for many people taking thalidomide. Taking the drug in the
evening can reduce the impact of drowsiness on daytime activities or dividing the dose may
help some individuals.
Neuropathy is one of the adverse factors that limits the use of thalidomide. Patients taking
thalidomide should be advised to report any new symptoms or worsening of pre-existing
ones. This can be difficult as many individuals with ENL will have some nerve damage but it
should not be assumed that deterioration in nerve function is due to ENL.
They should be allowed sufficient time to come to a decision. This may require more than
one meeting with the prescribing physician so that questions can be answered and important
points reiterated. It is important to emphasise to patients that they must not share their
thalidomide tablets with anyone else.
The informed consent obtained when an individual decides to take the drug should form
the basis of a contract.
The possibility of pregnancy should be excluded in women who are fertile. They should
then be advised to use two forms of contraception. All patients should be seen on a monthly
basis and women should have a pregnancy test performed at each visit. In the early phase of
thalidomide therapy more frequent clinic attendances may be required.
The FDA when it approved the use of thalidomide introduced the System for Thalidomide
Education and Prescribing Safety (S.T.E.P.S.) programme. This is a mandatory registry and
includes authorised patients, prescribers and pharmacies. The registered prescriber must
contact the S.T.E.P.S programme and answer questions concerning the prescription of
thalidomide including the dose. The patient must also contact the programme and answer a
set of questions designed to ensure safe use of the drug. Once both the prescriber and patient
have done this successfully the prescription is authorised. Finally a registered pharmacist
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calls the programme to see if the prescription for thalidomide has been authorised and can be
dispensed. A similar procedure must be followed in Europe and Australia.
The S.T.E.P.S programme in the USA appears to work well. Six thousand female patients
at risk of pregnancy entered the programme up to the end of 2004. They were taking
thalidomide for conditions including myeloma, other neoplasia, rheumatological and
dermatological diseases. Only 0·2% were taking thalidomide for the management of ENL.
There were three pregnancies, two of which were identified as a result of the programme
before thalidomide was prescribed. The third case, a 44-year old woman with melanoma had
had a negative pregnancy test on day eight of her menstrual cycle before starting thalidomide
and two more negative tests during the first month of treatment. On day 35 she had a positive
test and thalidomide was stopped. The test result was confirmed the following day and a week
later. Four weeks after the first positive test she had a spontaneous abortion.57
Pregnancy prevention programmes require good healthcare infrastructure, time and
finance. These things are often not readily available in leprosy-endemic countries.
Only one month’s supply of thalidomide should be prescribed to ensure that regular
assessments and pregnancy tests are negative before further drugs are dispensed.
In severe ENL we suggest starting with thalidomide at a dose of 400 mg nocte to control
the main symptoms. This should be reduced to 300 mg daily as soon as possible, usually
within a week. The thalidomide is then reduced more slowly by 100 mg each month. During
this period the patient should be assessed to ensure the ENL has not deteriorated.
Any deterioration should be treated by increasing the thalidomide again for a few weeks.
The patient should be stabilised on the lowest dose of thalidomide that controls the disease
and continue at this dose for a period of 2-3 months.
A patient already on steroids may have ENL that is more difficult to control. In the
experience of one of the authors, controlling ENL by replacing steroids with thalidomide is
much more difficult than when using thalidomide from the beginning. It may take several
weeks to reduce the steroids and obtain control with thalidomide alone. This is a further
argument for switching to thalidomide early although in many settings steroids will be used
first. The steroids should be reduced gradually aiming for control of ENL with thalidomide
alone within 6 weeks. A further indication for switching to thalidomide would be any
suggestion of early amyloidosis, especially persistent mild albuminuria, despite treatment
with steroids.
WHO has issued conflicting statements with respect to the use of thalidomide. The drug is
acknowledged as an effective treatment for ENL by the WHO Expert Committee on
Leprosy31 but other publications state that WHO does not support the use of thalidomide in
ENL58 or even more emphatically that there is no role for thalidomide in the management of
leprosy.59 Dr Pannikar, Communicable Diseases (Leprosy Group) WHO, published an article
stating that ENL reactions are ‘: : :rare: : :(mostly) mild in nature: : :and do not require any
specific treatment except with some analgesics/antipyretics.’60 This view does not concur
with the published evidence on the importance of ENL, albeit to small numbers of patients
and provoked a vigorous response from leprosy workers61 – 63 around the world arguing for
the place of thalidomide in the management of ENL.
There are little good data concerning the effect of thalidomide on the neural and ocular
manifestations of ENL which are disabling and occur commonly.1 There are case series
suggesting that thalidomide may be effective in treating neuritis64 and iritis,65 which are
usually managed with corticosteroids.
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Adverse effects of thalidomide
TERATOGENICITY
Thalidomide causes a wide range of abnormalities and almost any organ system may be
affected.66 The most characteristic abnormality is limb reduction with the upper limbs being
more frequently affected than the lower limbs. The ears and eyes are the second most
frequently affected group after the limbs.
The teratogenic effect of thalidomide occurs when it is taken between days 20 and 36 after
conception. Thalidomide appears to intercalate into guanine rich promoter sequences of
insulin growth factor-1 (IGF-1) and fibroblast growth factor (FGF) genes.67 IGF-1 and FGF
act in combination to stimulate limb initiation and thalidomide has been shown to suppress
guanine rich promoter sequences in myeloma cells.68
Even if the teratogenic enantiomer in humans could be determined and separate R- and
S-thalidomides produced, because each readily reverts to a racemic mixture under
physiological conditions the possibility of teratogenic fetal damage would remain.36
The drug is present in human semen after ingestion69 but there are no reports of
teratogenicity caused through exposure to semen of men who are taking thalidomide, but it
has occurred in experiments with rabbits via this route.70
NEUROPATHY
A prospective study of 135 patients with dermatological conditions treated with thalidomide
demonstrated that a peripheral neuropathy occurred in 20% of individuals during the first year
of treatment.71 The neuropathy manifests as painful paraesthesia and/or numbness. The feet
are affected before the hands in a glove-stocking type distribution. Weakness may also occur.
The neuropathy correlates with the daily dose administered and is permanent in 50%. It may
progress for some time after cessation of the drug72 and any improvement that does occur
may do so slowly.
Nerve conduction studies show a predominantly sensory, axonal, length-dependent
neuropathy. Nerves show loss of large myelinated fibres and little inflammation when
examined histologically.72 Reduction of sensory nerve action potential amplitude and relative
conservation of nerve conduction velocities were the electrophysiological features of
thalidomide neuropathy in 13 individuals without leprosy who were taking thalidomide for
severe dermatological conditions.73 There are no data concerning neuropathy attributable to
thalidomide in individuals with ENL.
THROMBOEMBOLISM
Thalidomide when used as monotherapy in myeloma is associated with thromboembolism in 3%
of patients.74 The rate increases to 14% when thalidomide is combined with dexamethasone.
A single case of iliac deep vein thrombosis has been reported in a woman with ENL treated with a
combination of thalidomide, prednisolone, dexamethasone and cyclophosphamide.75
CUTANEOUS
Adverse effects on the skin have been reported to occur in 3% of myeloma patients receiving
thalidomide.74 Rarer severe cutaneous adverse reactions such as erythema multiforme,
erythroderma and toxic epidermal necrolysis have been attributed to thalidomide.40
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OTHER ADVERSE EFFECTS
Thalidomide frequently causes somnolence and constipation which may limit the usefulness
of the drug. The degree of somnolence is severe in up to 11% of patients.74 Other adverse
effects which may lead to discontinuation of thalidomide include dizziness, nausea,
peripheral oedema, neutropenia and amenorrhoea. Hypothyroidism has been reported
following the administration of thalidomide.76
Other Drugs
Pentoxifylline
This methylxanthine derivative used is in the management of peripheral vascular disease.
It has been shown to inhibit the production of TNF both in vitro and in vivo.77 A randomised
double blind study from Brazil of pentoxifylline 1·2 g daily in ENL demonstrated that it was
not as effective as thalidomide 300 mg daily.46 Published small case series show a limited
response of ENL to pentoxifylline at daily doses ranging from 1200–2400 mg.78 – 81
Aspirin and indomethacin
Aspirin has been evaluated in the treatment of ENL in three double blind controlled trials and
indomethacin in one. In one study both were less effective than Prednisolone82 and in another
trial aspirin was less effective than thalidomide.49 In the third study aspirin was compared
with colchicine in the management of ENL and both were equally effective in mild disease.83
Cyclosporin
The role of cyclosporin in ENL was thought to be promising following in vitro studies, but
published clinical data are restricted to a short series of three patients in whom it was largely
effective.84,85
Methotrexate86 and azathioprine.28
Both have both been reported to be useful in the management of refractory ENL when used in
conjunction with systemic steroids. Both men and women are advised not to start a pregnancy
while on methotrexate and for 6 months after stopping it. Azathioprine appears to be safe in
pregnancy.87
Zafirlukast
The leukotriene antagonist zafirlukast has been tried in an open phase II cohort trial using an
initial dose of 40 mg twice daily. It was effective in six patients with ENL although outcome
measures were not defined.88
Infliximab
The successful use of this chimeric monoclonal antibody, which suppresses the biological
activity of TNF by specifically binding to it, has been reported in a single case of recurrent
ENL treated in the Netherlands.89
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Colchicine
Treatment with colchicine appeared beneficial in two small case series.90,91 A subsequent
controlled study of five patients failed to demonstrate any impact of colchicine on steroid
requirement.92 A second controlled study comparing colchicine with aspirin showed a
marginal benefit in moderate disease.83
Chloroquine
Chloroquine is used to manage ENL but there is little evidence from controlled studies that it
is effective.82 Chloroquine produced quicker improvement of neuritis than indomethacin and
aspirin in a small double blind study.49
Zinc
Oral zinc (220 mg per day) has been used in two small uncontrolled studies from India that
reported reduced steroid requirements but it is not possible to make any definite conclusions
about the clinical effect.93,94
The challenge of ENL
ENL reactions are usually recurrent or chronic and predicting which clinical pattern an
individual’s disease will follow is not possible.6 This poses a problem in deciding which
therapy to institute in the early stages of the disease. A person who will require numerous or
prolonged courses of high dose steroids might possibly be managed differently from the
outset if such a prognosis were predictable. It has also been reported that patients treated
initially with steroids have a reduced response when changed to thalidomide but this has
never been formally tested and would be difficult to test.
The algorithm in Figure 2 is a suggested approach to the management of moderate and
severe ENL starting with prednisolone or thalidomide. It is not logical routinely to use
thalidomide and oral corticosteroids together to manage ENL. The available evidence does
not support this and patients are exposed to the potential adverse effects of both drugs.
The ILEP guidelines advocate considering using thalidomide for severe ENL if treatment
with corticosteroids and clofazimine is not effective. The duration of treatment required for
adequate management of ENL is uncertain regardless of which anti-reactional therapy is
used. The anxiety provoked by long-term immunosuppression or exposure to toxic drugs is
exacerbated by the frustration of relapse as therapy is tapered.
Individuals who require long-term corticosteroid therapy should be considered for steroid
sparing agents or therapies which may obviate the need for steroids. The adverse effects of
steroids may require dose reduction or discontinuation. Rarely there may be an absolute
contraindication to corticosteroids or tachyphylaxis to steroids may develop.
Deciding which alternative agents to use will be guided by availability, patient
preferences and specific risks associated with individual treatments. The individuals
requiring a second line agent are likely to need it for many months to prevent recurrence.
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Future Directions
There is a need for further research in the management of ENL, acknowledging that it is
difficult to perform trials in a condition which spontaneously fluctuates. Topics that need
urgent attention include:
1. The development of a validated scale for measuring ENL reactions.
2. A direct comparison of thalidomide and corticosteroids in the management of ENL. Given
the recurrent nature of ENL any such study should use time to next episode of ENL as an
outcome measure as well as the response of clinical parameters. A comparison of
thalidomide alone versus a combination of thalidomide and prednisolone using nerve pain,
nerve tenderness and nerve function impairment as outcome measures is also warranted.
3. An assessment of the neurotoxicity of thalidomide in leprosy patients and its clinical
relevance in a situation where uncontrolled ENL may itself cause permanent
neuropathy.95 It is unclear why leprologists have failed to pick up clinically relevant
neuropathy associated with the use of thalidomide.
4. The implementation of the robust patient monitoring schemes that already exist and are
vital to prevent thalidomide embryopathy. The 34 cases of thalidomide embryopathy born
between 1965 and 1996 in South America show a continuing need for improvement.96
Figure 2. Algorithm for managing moderate and severe ENL.
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National programmes and organisations involved in the delivery of leprosy care should
develop a consensus on the role of thalidomide in the management of ENL and the safest way
to use the drug in leprosy endemic settings. Quality of life studies in patients with ENL would
help to determine the social and financial impact of this condition, and the socio-economic
importance of effective control.
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